2342 — TransGenic Income Statement

0.000.00%

Last trade - 00:00

Consumer CyclicalsHighly SpeculativeMicro CapNeutral

Annual income statement for TransGenic, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Tanshin
Standards:	JAS	JAS	JAS	JAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	12,577	11,430	13,083	13,005	13,174
Cost of Revenue
Gross Profit	3,836	1,995	2,249	2,167	2,434
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	11,264	12,027	13,056	13,622	13,500
Operating Profit	1,312	-598	27.2	-617	-325
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	2,768	-332	43.1	-676	-193
Provision for Income Taxes
Net Income After Taxes	1,860	-440	3.99	-1,091	-83.3
Minority Interest
Net Income Before Extraordinary Items
Net Income	1,876	-410	4.09	-1,090	-63.1
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	1,876	-410	4.08	-1,090	-63.1
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	76.6	-0.013	5.69	-47.3	17.1
Dividends per Share
Special Dividends per Share